Acute subjective effects after smoking joints containing up to 69 mg Δ9-tetrahydrocannabinol in recreational users: a randomized, crossover clinical trial
- PMID: 24879495
- DOI: 10.1007/s00213-014-3630-2
Acute subjective effects after smoking joints containing up to 69 mg Δ9-tetrahydrocannabinol in recreational users: a randomized, crossover clinical trial
Abstract
Rationale: An increase in the potency of the cannabis cigarettes has been observed over the past three decades.
Objectives: In this study, we aimed to establish the impact of Δ9-tetrahydrocannabinol (THC) on the rating of subjective effects (intensity and duration of the effects), up to 23 % THC potency (69 mg THC) among recreational users.
Methods: Recreational users (N = 24) smoked cannabis cigarettes with four doses of THC (placebo 29, 49 and 69 mg of THC) on four separate test days in a randomized, double-blind, placebo-controlled, crossover study. The participants filled in three different questionnaires measuring subjective effects during the exposure up to 8 h post-smoking. The 'high' feeling, heart rate, blood pressure and THC serum concentrations were also regularly recorded during these 8 h.
Results: THC significantly increased the high feeling, dizziness, dry-mouthed feeling, palpitations, impaired memory and concentration, and 'down', 'sedated' and 'anxious' feelings. In addition, THC significantly decreased alertness, contentment and calmness. A cubic relationship was observed between 'feeling the drug' and 'wanting more'. The THC-induced decrease in 'feeling stimulated' and increase in anxiety lasted up to 8 h post-smoking. Sedation at 8 h post-smoking was increased by a factor of 5.7 with the highest THC dose, compared to the placebo.
Conclusions: This study shows a strong effect of cannabis containing high percentages of THC on the rating of subjective effects. Regular users and forensic toxicologists should be aware that the THC-induced increase in 'feeling sedated' continues longer with a 69 mg THC dose than with a 29 mg THC dose.
Similar articles
-
Cognitive and psychomotor effects in males after smoking a combination of tobacco and cannabis containing up to 69 mg delta-9-tetrahydrocannabinol (THC).Psychopharmacology (Berl). 2009 May;204(1):85-94. doi: 10.1007/s00213-008-1440-0. Epub 2008 Dec 20. Psychopharmacology (Berl). 2009. PMID: 19099294 Clinical Trial.
-
Delta-9-tetrahydrocannabinol (THC) serum concentrations and pharmacological effects in males after smoking a combination of tobacco and cannabis containing up to 69 mg THC.Psychopharmacology (Berl). 2008 Dec;201(2):171-81. doi: 10.1007/s00213-008-1260-2. Epub 2008 Aug 10. Psychopharmacology (Berl). 2008. PMID: 18695931 Clinical Trial.
-
Comparison of the subjective effects of Delta(9)-tetrahydrocannabinol and marijuana in humans.Psychopharmacology (Berl). 2002 Jun;161(4):331-9. doi: 10.1007/s00213-002-1033-2. Epub 2002 Apr 19. Psychopharmacology (Berl). 2002. PMID: 12073159 Clinical Trial.
-
Tolerability of High-Dose Oral Δ9-THC: Implications for Human Laboratory Study Design.Cannabis Cannabinoid Res. 2024 Apr;9(2):437-448. doi: 10.1089/can.2023.0209. Epub 2024 Feb 19. Cannabis Cannabinoid Res. 2024. PMID: 38377580 Review.
-
Duration of Neurocognitive Impairment With Medical Cannabis Use: A Scoping Review.Front Psychiatry. 2021 Mar 12;12:638962. doi: 10.3389/fpsyt.2021.638962. eCollection 2021. Front Psychiatry. 2021. PMID: 33790818 Free PMC article.
Cited by
-
Epidemiology of drug driving: protocol from a national Canadian study measuring levels of cannabis, alcohol and other substances in injured drivers.BMC Public Health. 2020 Jul 6;20(1):1070. doi: 10.1186/s12889-020-09176-5. BMC Public Health. 2020. PMID: 32631283 Free PMC article.
-
Cannabinoid effects on responses to quantitative sensory testing among individuals with and without clinical pain: a systematic review.Pain. 2020 Feb;161(2):244-260. doi: 10.1097/j.pain.0000000000001720. Pain. 2020. PMID: 31613869 Free PMC article.
-
Marijuana Use and Hypothalamic-Pituitary-Adrenal Axis Functioning in Humans.Front Psychiatry. 2018 Oct 1;9:472. doi: 10.3389/fpsyt.2018.00472. eCollection 2018. Front Psychiatry. 2018. PMID: 30327619 Free PMC article. Review.
-
Objective Identification of Cannabis Use Levels in Clinical Populations Is Critical for Detecting Pharmacological Outcomes.Cannabis Cannabinoid Res. 2022 Dec;7(6):852-864. doi: 10.1089/can.2021.0068. Epub 2021 Nov 18. Cannabis Cannabinoid Res. 2022. PMID: 34793254 Free PMC article.
-
Controlled vaporized cannabis, with and without alcohol: subjective effects and oral fluid-blood cannabinoid relationships.Drug Test Anal. 2016 Jul;8(7):690-701. doi: 10.1002/dta.1839. Epub 2015 Aug 10. Drug Test Anal. 2016. PMID: 26257143 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous